Anaesthesia for Castration of Piglets: Comparison Between Intranasal and Intramuscular Application of Ketamine, Climazolam and Azaperone

Total Page:16

File Type:pdf, Size:1020Kb

Anaesthesia for Castration of Piglets: Comparison Between Intranasal and Intramuscular Application of Ketamine, Climazolam and Azaperone Originalarbeiten Anaesthesia for castration of piglets: Comparison between intranasal and intramuscular application of ketamine, climazolam and azaperone S. M. Axiak1, N. Jäggin1, S. Wenger1, M. G. Doherr2, U. Schatzmann1 1Division of Anaesthesiology and 2Division of Clinical Veterinary Research, Department of Clinical Veterinary Medicine, University of Bern Summary Kurznarkose zur Kastration von neugeborenen Ferkeln: Vergleich zwischen intranasaler und intramuskulärer Applikation von Ketamin, Climazolam und Azaperon The aim of this study was to compare the effect of Ziel dieser Studie war es, eine Kombination aus an anaesthetic combination given either intramus- Ketamin, Azaperon and Climazolam intranasal oder cularly (IM) or intranasally (IN) for castration of intramuskulär Kastrationsferkeln zur Narkoseein- piglets. Forty piglets aged 4 to 7 days were ran- leitung zu verabreichen und ihre Wirkung verglei- domly assigned to receive a mixture of ketamine 15 chen. 40 Ferkel im Alter zwischen 4–7 Tagen er- mg kg-1, climazolam 1.5 mg kg-1 and azaperone hielten 15 mg/kg KGW Ketamine, 1.5 mg/kg 1.0 mg kg-1, IN or IM, 10 minutes prior to castra- KGW Climazolam und 1 mg/kg KGW Azaperon tion. Physiological parameters were measured. Cas- intranasal (IN) oder intramuskulär (IM) zehn Mi- tration was videotaped for evaluation by 3 inde- nuten vor der Kastration. Physiologische Parameter pendent observers using a scoring system. Reaction wurden aufgezeichnet. and vocalization to the skin incision and cutting of Die Kastration wurde gefilmt und von drei unab- spermatic cord was evaluated and scored (0 = no hängigen Beobachtern mittels einem Punktesys- reaction, 16 = strong reaction). The IN group had tem (Kastrationsscore) beurteilt, wobei bei den a significantly higher (P < 0.01) castration score, Hautschnitten und der Durchtrennung der Samen- compared to the IM group. There was an associa- stränge jeweils Lautäusserung und Abwehrbewe- tion between castration score and room tempera- gung protokolliert wurde (0 = keine Reaktion, 16 ture in the IN group (with temperatures below 18 = starke Reaktion). Die Gruppe IN verzeichnete ºC associated with a higher castration scores (P < signifikant höhere Kastrationsscores als die IM 0.001). Heart rate was significantly higher 10 min- Gruppe (P < 0.01). Zwischen dem Kastrations- utes after castration in the IN group (P < 0.05). score und der Raumtemperatur war eine signifi- Respiratory rate was significantly higher in the IM kante Korrelation (bei Raumtemperatur <18°C group at time points -5, -1, 10, 20 and 30 (P < höhere Kastrationsscores) in der Gruppe IN. Die 0.05). The IN group was walking significantly (P < Herzfrequenz war signifikant höher in der Gruppe 0.0001) faster than the IM group. In conclusion, IM 10 Minuten nach der Kastration (P < 0.05) und this combination provides effective anaesthesia for die Atemfrequenz war zu den Zeitpunkten -5, -1, routine castration of newborn piglets when admin- 10, 20 und 30 signifikant höher in der IN Gruppe istered IM. IN administration provided shorter re- (P < 0.05). Die Aufwachphase war kürzer in der IN covery times but had significantly higher castration Gruppe (P < 0.0001). Die Kombination erzeugt scores. eine gute Anästhesie zur Ferkelkastration bei IM Verabreichung, wogegen die IN Gruppe kürzere Aufwachphasen aufwies, aber auch signifikant hö- here Kastrationsscores. Keywords: anaesthesia, castration, intramuscular, intranasal, Schlüsselwörter: Anästhesie, Kastration, intramuskulär, in- piglets tranasal, Ferkel Introduction Anaesthesia and analgesia for piglet castration is an an- according to Swiss law by 2009. The technique used imal welfare imperative and is currently required by should result in significant reduction or elimination of law in Norway and pain elimination will be necessary pain and stress for the piglets and should also be short Schweiz.Arch.Tierheilk. S. M. Axiak et al., Band 149, Heft 9, September 2007, 395–402395 ©2007 by Verlag Hans Huber, Hogrefe AG, Bern DOI 12.1024/0036-7281.149.09.395 Anaesthesia for castration of piglets acting, economical, ecologic, residue free, easy to use and azaperone 1.0 mg kg-1 were administered in com- and have a large therapeutic range. Several investiga- bination either intramuscularly (IM) or intranasally tions have been undertaken to find an ideal method. (IN) prior to the castration of the piglets. Just prior to Intramuscular ketamine and azaperone is effective but the experiment, the male piglets were sorted and prolonged recovery remains a problem (Kmiec, 2005). weighed unfasted. Pairs assigned were of the same lit- Local anaesthetic techniques are performed routinely ter and had less than 10% difference in body weight. in Norway since 2002, but do not completely block Each pair received anaesthesia on the same day, se- the nociceptive response (Haga and Ranheim, 2005). quentially. The first member of each pair was ran- Inhaled carbon dioxide provides reliable unconscious- domly assigned by a computer generated random ness, but unwanted side effects including hyperventi- number chart to receive either the IM or IN admin- lation, agitation and gasping make this technique un- istration route, while the second member of each pair acceptable (Kohler et al., 1998). Isoflurane, via a special received the other. double mask to reduce pollution of the environment and exposure to the staff, has been shown to be a fast, Anaesthesia safe and practical method (Walker et al., 2004). How- ever, handling, equipment costs and exposure con- Ketamine (Ketamin-HCl-Lösung 173 mg ml-1; Dr. E. cerns have to date limited its acceptance. Intranasal de- Graeub AG, Bern, Switzerland), climazolam (Climazo- livery systems are widely used today in human lam-Lösung 30 mg ml-1; Dr. E. Graeub AG, Bern, paediatric medicine to deliver medication in a pain- Switzerland) and azaperone (Stresnil® 40 mg ml; and stress-free manner. Intranasal ketamine and mida- Janssen Pharmaceutica, Beerse, Belgium) were com- zolam, in combination, have been used successfully for bined in saline to give a final concentration that yielded sedation of children (Louon and Reddy, 1994). An in- ketamine 15 mg kg-1, climazolam 1.5 mg kg-1 and aza- tranasal system would be “needle-less” making it more perone 1 mg kg-1 when dosed at 0.2 ml kg-1. The drugs desirable for on the farm use, as needle injury to both were mixed less than 12 hours prior to the start of the administrator and piglet can be avoided. experiments and stored at room temperature. The objectives of this study were 1) to compare the Administration of drugs commenced 10 minutes prior use of intranasal versus intramuscular administration to castration. IM administration was performed with a techniques and 2) evaluate cardiovascular effects, de- 1 ml syringe (Injekt – F®; Braun, Melsungen, Ger- gree of nociception, body temperature change and re- many) and a 0.6 × 25 mm needle (Sterican®; Braun, covery time when ketamine, climazolam and azaper- Melsungen, Germany) into the right neck muscle. A one are used in combination for castration of four to human nasal spray device, which dispensed 0.1 ml per seven day old piglets. spray, (AccuPump®, Saint-Gobain Calmar GmbH, Hemer, Germany) was used for IN administration into both nostrils. For administration, the piglets were held Animals, Material and Methods in a sternal position by the investigator with the head fixed by hand at a 45° angle. Post-administration piglets were placed into a heated straw box for obser- Animals vation. Five minutes after administration, piglets were All experiments were performed at the same commer- assessed for relaxation and recumbency. If recumbency cial Bio-Suisse organic swine facility over a 6-month was not achieved by 10 minutes after administration, period from July 2005 to January 2006. Forty purebred the animals were redosed with half of the original vol- Large White male piglets, aged 4 to 7 days, from 10 dif- ume and left undisturbed for 10 more minutes. Num- ferent litters were included in the study. Numbers are ber of animals requiring redosing was recorded. presented as medians with upper and lower 95% con- fidence intervals (CI). The median body weight of all Castration animals was 2.24 (2.1; 2.65) kg and the median age was 5 (5; 6) days. All animals were deemed healthy based on Castration was performed 10 minutes after the last ad- clinical examination, had normal testicular anatomy ministration of anaesthetic agents by the same inves- and no concurrent treatments. The Committee for An- tigator. Animals were placed in dorsal recumbency imal Experimentation of the Kanton Bern of Switzer- and the hind legs were fixed cranially with a velcro land approved the study. strap. The electrocardiogram was monitored through- out the procedure using a standard base-apex lead configuration (Datex S5®, Datex-Ohmeda, Finland). Experimental Design The scrotom was washed with a dilute chlorhexadine A randomized and blinded experimental study de- scrub (Lifoscrub®, B-Braun-Medical AG, Emmen- sign, using matched pairs for litter and weight, was brücke, Switzerland) and the castration was per- used. Ketamine 15 mg kg-1, climazolam 1.5 mg kg-1 formed with a scalpel blade (Packagon #10 sterile sin- S. M. Axiak et al., Band 149, Heft 9, September 2007, 395–402396 Schweiz.Arch.Tierheilk. ©2007 by Verlag Hans Huber, Hogrefe AG, Bern Anaesthesia for castration of piglets gle use scalpel, Lance Paragon LTD, Sheffield, Eng- Recovery land). A small skin incision was made in the scrotum Sarmazenil (Sarmasol® 1 mg ml-1, Dr. E. Gräub AG, directly over each testicle. Pressure was applied to each Bern, Switzerland) at a dose of 0.2 mg kg-1 was ad- testicle, until it emerged from the incision. The testi- ministered, using the same route as for the prior cle was then gently pulled from the incision and the agents, 30 minutes after castration for antagonization spermatic cord and vessels were cut. The entire castra- of climazolam. Time to walking from drug adminis- tion was recorded on video for later castration scor- tration was recorded when the piglets were able to ing.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Understanding Benzodiazephine Use, Abuse, and Detection
    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61K 31/5517 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61P 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/551 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/NL20 14/050781 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 November 2014 (13.1 1.2014) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/903,433 13 November 2013 (13.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Total Intravenous Anesthesia with Midazolam, Ketamine
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2010 Total invtravenous anesthesia with midazolam, ketamine, and xylazine or detomidine following induction with tiletamine, zolazepam, and xylazine in red deer (Cervus elaphus hippelaphus) undergoing surgery Auer, U ; Wenger, S ; Beigelböck, C ; Zenker, W ; Mosing, M Abstract: Sixteen captive female red deer were successfully anesthetized to surgically implant a telemetry system. The deer were immobilized with (mean±SD) 1.79±0.29 mg/kg xylazine and 1.79±0.29 mg/kg tiletamine/zolazepam given intramuscularly with a dart gun. Anesthesia was maintained for 69±2 min using a total intravenous protocol with a catheter placed in the jugular vein. Group X received xylazine (0.5±0.055 mg/kg/hr) and group D, detomidine (2±0.22 µg/kg/hr), both in combination with ketamine (2±0.02 mg/kg/hr) and midazolam (0.03±0.0033 mg/kg/hr), as a constant rate infusion. Anesthesia was reversed with 0.09±0.01 mg/kg atipamezole and 8.7±1.21 µg/kg sarmazenil given intravenously in both groups. These drug combinations provided smooth induction, stable anesthesia for surgery, and rapid recovery. Respiratory depression and mild hypoxemia were seen, and we, therefore, recommend using supplemental intranasal oxygen. DOI: https://doi.org/10.7589/0090-3558-46.4.1196 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-36361 Journal Article Originally published at: Auer, U; Wenger, S; Beigelböck, C; Zenker, W; Mosing, M (2010).
    [Show full text]
  • Untersuchung Über Den Einsatz Von Brotizolam Zur Reduktion Kastrationsbedingter Schmerzen Beim Männlichen Saugferkel
    Aus der Klinik für Schweine in Oberschleißheim (Vorstand: Prof. Dr. Dr. Karl Heinritzi) der Tierärztlichen Fakultät der Ludwig-Maximilians-Universität München Untersuchung über den Einsatz von Brotizolam zur Reduktion kastrationsbedingter Schmerzen beim männlichen Saugferkel Inaugural-Dissertation zur Erlangung der tiermedizinischen Doktorwürde der Tierärztlichen Fakultät der Ludwig-Maximilians-Universität München von Iris Breitinger aus Tübingen München 2009 Gedruckt mit Genehmigung der Tierärztlichen Fakultät der Ludwig-Maximilians-Universität München Dekan: Prof. Dr. J. Braun Referent: Prof. Dr. Dr. K. Heinritzi Korreferent: Prof. Dr. R. Köstlin Tag der Promotion: 6. Februar 2009 Meinen Eltern & „Wutz“- in loving memory Inhaltsverzeichnis I Inhaltsverzeichnis 1. EINLEITUNG........................................................................................1 2. LITERATURÜBERSICHT.....................................................................2 2.1 Die chirurgische Kastration männlicher Saugferkel........................................ 2 2.1.1 Gesetzliche Grundlagen ................................................................................. 3 2.1.2 Indikationen für die Kastration männlicher Schweine ..................................... 5 2.1.2.1 Ebergeruch ..................................................................................................... 5 2.1.2.2 Unterdrückung des Sexualverhaltens............................................................. 7 2.2 Alternativen zur chirurgischen Kastration ......................................................
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]